Evidence map›Paper›PMID 29671056›Full record

ArticleBrain structure & function2018

Progressive symptom-associated prefrontal volume loss occurs in first-episode schizophrenia but not in affective psychosis.

Toshiyuki Ohtani, Elisabetta Del Re, James J Levitt, Margaret Niznikiewicz, Jun Konishi, Takeshi Asami, Toshiro Kawashima, Tomohide Roppongi, Paul G Nestor, Martha E Shenton and 2 more

Abstract read
In one paragraph

Article in Brain structure & function, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Toshiyuki OhtaniLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Elisabetta Del ReLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
James J LevittLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Margaret NiznikiewiczLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Jun KonishiLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Takeshi AsamiLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Toshiro KawashimaLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Tomohide RoppongiLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Paul G NestorLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Martha E ShentonLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA. shenton@bwh.harvard.edu.
Dean F SalisburyLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Robert W McCarleyLaboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St., Brockton, MA, 02301, USA.
Brigham and Women's Hospital · USHarvard University · USChiba University · JPSaga University · JPSignature Healthcare Brockton Hospital · USUniversity of Pittsburgh · USYokohama City University · JP

Funding

Vulnerability to Progression SchizophreniaP50MH080272 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MCCARLEY, ROBERT W · 2007 to 2011
$9.9M
NEUROPHYSIOLOGICAL STUDIES OF SCHIZOPHRENIAR01MH040799 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MCCARLEY, ROBERT W · 1986 to 2011
$6.5M
COMPUTERIZED IMAGE ANALYSES OF MR SCANS IN SCHIZOPHRENIAR01MH050740 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHENTON, MARTHA E. · 1999 to 2009
$4.4M
Identifying mechanisms of response to therapeutic intervention in clinical high risk (CHR) for psychosis: a bridge to treatmentR01MH111448 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, HUIJUN, NIZNIKIEWICZ, MARGARET A · 2016 to 2023
$4.4M
BIOLOGICAL BASIS OF SCHIZOTYPAL PERSONALITY DISORDERR01MH052807 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MCCARLEY, ROBERT W · 1994 to 2009
$3.3M
Brain Activity and Language Comprehension in PsychosisR01MH058704 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI SALISBURY, DEAN F · 2001 to 2010
$2.5M
Genetic Determinants of Schizophrenia Intermediate PhenotypesR01MH092380 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI PETRYSHEN, TRACEY · 2012 to 2015
$2.4M
Clinical Symptons &Brain Abnormalities in SchizophreniaK05MH070047 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHENTON, MARTHA E. · 2004 to 2008
$581k
VENTRICLES, CORPUS CALLOSUM, SYMPTOMS & MIR137 IN LARGE N STUDY OF SCHIZOPHRENIAR21MH109819 · NIMH · HARVARD MEDICAL SCHOOL · PI DEL RE, ELISABETTA C. · 2016 to 2017
$431k
CLINICAL SYMPTOMS &BRAIN ABNORMALITIES IN SCHIZOPHRENIAK02MH001110 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHENTON, MARTHA · 1994 to 2003
$415k
Genetic Topography of Brain Morphology in Relation to Language in Large N Study of SchizophreniaR03MH122759 · NIMH · HARVARD MEDICAL SCHOOL · PI DEL RE, ELISABETTA C. · 2021 to 2022
$130k
Development of MR Biomarkers of Brain Injury in Acute and Chronic mTBII01RX000928 · VA · VA BOSTON HEALTH CARE SYSTEM · PI SHENTON, MARTHA E. · 2015 to 2017
–
CSRD VA I01 CX000176NIMH NIH HHS K05 MH070047NIMH NIH HHS P50 MH080272NIMH NIH HHS R01 MH040799NIMH NIH HHS R01 MH050740NIMH NIH HHS R01 MH052807NIMH NIH HHS R01 MH058704NIMH NIH HHS R01 MH092380NIMH NIH HHS R01 MH111448NIMH NIH HHS R03 MH122759NIMH NIH HHS R21 MH109819RRD VA I01 RX000928
6 · The paper itself

Abstract

Although smaller gray matter volumes (GMV) in the prefrontal cortex (PFC) in schizophrenia and bipolar disorder have been reported cross-sectionally, there are, to our knowledge, no reports of longitudinal comparisons using manually drawn, gyrally based ROI, and their associations with symptoms. The object of this study was to determine whether first-episode schizophrenia (FESZ) and first-episode affective psychosis (FEAFF) patients show initial and progressive PFC GMV reduction in bilateral frontal pole, superior frontal gyrus (SFG), middle frontal gyrus (MFG), and inferior frontal gyrus (IFG) and examine their symptom associations. Twenty-one FESZ, 24 FEAFF and 23 healthy control subjects (HC) underwent 1.5T MRI with follow-up imaging on the same scanner ~ 1.5 years later. Groups were strikingly different in progressive GMV loss. FESZ showed significant progressive GMV loss in the left SFG, bilateral MFG, and bilateral IFG. In addition, left MFG and/or IFG GMV loss was associated with worsening of withdrawal-retardation and total BPRS symptoms scores. In contrast, FEAFF showed no significant difference in GMV compared with HC, either cross-sectionally or longitudinally. Of note, FreeSurfer run on the same images showed no significant changes longitudinally.

Indexed as

Disease ProgressionAdolescentAdultAffective Disorders, PsychoticBrain MappingCorrelation of DataCross-Sectional StudiesFemaleFunctional LateralityGray MatterHumansImage Processing, Computer-AssistedLongitudinal StudiesMaleMiddle AgedPrefrontal CortexFirst-episode affective psychosisFirst-episode schizophreniaLongitudinal follow-upMagnetic resonance imaging (MRI)Prefrontal cortex

Identifiers

PMID29671056
PMCPMC6010171
OpenAlexW2801877944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.